Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build ...

Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...

Novartis has announced a five-year commitment to the fight against malaria, saying it plans to invest more than $100m to advance R&D of next-generation drugs for the disease becomes resistant to ...

CEO Vas Narasimhan pointed out that the foundations were being established for the drug to become a “very significant brand” for Novartis. Still, the CEO noted that it would be a “long ...

The news sparked a near-5% rise in Novartis’ share price. Chief executive Vas Narasimhan said performance was good “across all key growth brands and geographies” and “gives us continued ...

Despite challenges such as currency fluctuations and International Reference Pricing (IRA), Novartis remains optimistic about its future growth. The company's CEO, Vas Narasimhan, has discussed ...

Jay Bradner, head of Novartis’ drug discovery, talks to pharmaphorum about the firm’s drive to transform itself into 'a medicine and data science company ...

Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront. The Italian ...